California Peptide Research, Inc. announces BPA with the NIH
April 15, 2010 — California Peptide Research, Inc. (CPRI) announced today it has been awarded a blanket purchase agreement (BPA) by the National Institutes of Health (NIH) for its peptide products and consulting services. The BPA is effective April 15, 2010 and has no purchase limit for the NIH research community.
According to the terms of the BPA, NIH researchers can access a complete catalog of custom and catalog peptides and services needed to facilitate experimental research and improve outcomes. “California Peptide Research, Inc. has worked with the NIH for many years helping address critical needs in the research labs. This BPA is an important contractual vehicle for expanding our presence with the NIH and making the procurement of peptides more seamless,” said Fabio Simi, president of California Peptide Research, Inc. “We are privileged to serve NIH and are appreciative to be awarded this contract.”
About California Peptide Research, Inc.
California Peptide Research, Inc. (CPRI) provides high purity custom and catalog peptides. CPRI is a global manufacturing partner and supplier of reagents to leading life science organizations, government agencies and research professionals that require a wide variety of capabilities and service offerings. CPRI is located in Napa, California, was founded in 1993 and can be reached by calling (800) PEPTIDE.